GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
GeoVax Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 27, 2026
$0.23−0.01 (-4.53%)
Close on Oct 19, 2026
- Market cap
- $1.04M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$13.5850 (−98.35%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
GeoVax Labs, Inc. saw revenue fall 100.0% to $0 over the twelve months to Jun 30, 2026. Free cash flow was -$18.37M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$20.53M
TTM Q2 2026
Free cash flow
-$18.37M
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.04M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.59
- Dividend yield
- –
- Free cash flow yield
- -1768.73%
Fundamentals
- Revenue
- $0
- Net income
- -$20.43M
- Free cash flow
- -$18.37M
- Book value per share
- $0.39
- Diluted shares
- 5M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$0-100.0% YoY
Operating income
-$20.53M
Net income
-$20.43M
EPS, diluted
–
Free cash flow
-$18.37M
Reported periodTrailing twelve months